TORONTO, Nov. 13 /CNW/ - DELISTING REVIEW - Fralex Therapeutics Inc. (the
"Company") - TSX is reviewing the common shares (Symbol: FXI) and warrants
(Symbol: FXI.WT) of the Company with respect to meeting the continued listing
requirements. The Company has been granted 120 days in which to regain
compliance with these requirements, pursuant to the Remedial Review Process.
About TMX Group (TSX-X)
-----------------------
TMX Group's key subsidiaries operate cash and derivative markets for
multiple asset classes including equities, fixed income and energy. Toronto
Stock Exchange, TSX Venture Exchange, Montreal Exchange, Natural Gas Exchange,
Boston Options Exchange (BOX), Shorcan, Equicom and other TMX Group companies
provide trading markets, clearing facilities, data products and other services
to the global financial community. TMX Group is headquartered in Toronto with
offices in Montreal, Calgary and Vancouver. For more information about TMX
Group, visit our website at www.tsx.com.
